HYPERKALEMIA CLINICAL DATA Hyperkalemia is a medical condition in which levels of potassium in the blood are abnormally high. It occurs when renal potassium excretion is impaired by reductions in glomerular filtration rate, tubular flow, distal sodium delivery, or by disturbance of the renin–angiotensin–aldosterone system (RAAS). This potentially life-threatening electrolyte disorder occurs with greater frequency in patients with renal disease, heart failure, and in patients who use certain medications, such as renin–angiotensin–aldosterone system inhibitors (RAASis). For chronic hyperkalemia, treatment goals include normalizing potassium levels and maintaining of normokalemia in order to prevent further hyperkalemia episodes, in addition to allowing patients to optimize RAASi therapy. ASSESSMENT OF SINGLE-DOSE PATIROMER MONOTHERAPY IN HOSPITALIZED PATIENTS WITH ACUTE, NON–LIFE-THREATENING HYPERKALEMIA Hyperkalemia is a common electrolyte disorder in hospitalized patients; however, the clinical usefulness of administering patiromer for reduction of serum potassium levels in this setting is unknown. This informational video, led by Dr. Katherine DiPalo, reviews a recent study aimed to evaluate real-world outcomes associated with the use of patiromer monotherapy for non–life-threatening hyperkalemia at an institution that treats a racially and ethnically diverse urban population.